Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum
May 21 2019 - 08:30AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, today announced it will be presenting at the upcoming
Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at
the Waldorf Astoria Chicago on May 31, 2019.
Taking place on the first day of ASCO, the 5th Annual
Immuno-Oncology BD&L and Investment Forum is designed to bring
together thought leaders from cancer research institutes, patient
advocacy groups, pharma and biotech to facilitate partnering,
funding and investment. Genprex will be among the 30+ presentations
by listed and private biotechnology companies at the event.
Several networking opportunities are still available to
investors or delegates of other companies that may wish to meet the
Genprex team one-on-one. Those interested in setting a meeting are
asked to contact the company at investors@genprex.com.
Genprex will present at the Sachs 5th Annual Immuno-Oncology
BD&L and Investment Forum as follows:
Date: Friday, May 31, 2019Time: 11:10 a.m.
CTVenue: Waldorf Astoria ChicagoRoom: Sinclair
Ballroom
Genprex’s President and Chief Operating Officer, Julien Pham,
MD, MPH, will lead the company's presentation and will be available
for one-on-one meetings.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex on cancer. Risks and uncertainties
associated with Genprex and its lead product candidate Oncoprex are
described more fully under the caption “Risk Factors” and elsewhere
in our filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005199/en/
Genprex, Inc.(877) 774-GNPX (4679)
Investor RelationsGNPX Investor Relations(877) 774-GNPX
(4679) ext. #2investors@genprex.com
Media ContactGenprex Media RelationsKalyn Dabbs(877)
774-GNPX (4679) ext. #3media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2023 to Mar 2024